Douglas Cines médecin américain
Cines, Douglas B.
VIAF ID: 306188809 (Personal)
Permalink: http://viaf.org/viaf/306188809
Preferred Forms
-
- 100 0 _ ‡a Douglas Cines ‡c médecin américain
4xx's: Alternate Name Forms (5)
Works
Title | Sources |
---|---|
ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model | |
Advanced drug delivery systems for antithrombotic agents. | |
Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation | |
Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HIT. | |
The antigenic complex in HIT binds to B-cells via complement and complement receptor 2 (CD21). | |
Bad (or good) things come in small packages. | |
Biocompatible coupling of therapeutic fusion proteins to human erythrocytes | |
A chimeric platelet-targeted urokinase prodrug selectively blocks new thrombus formation | |
Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin. | |
Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody | |
Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier | |
Determinants of PF4/heparin immunogenicity | |
Distinct specificity and single-molecule kinetics characterize the interaction of pathogenic and non-pathogenic antibodies against platelet factor 4-heparin complexes with platelet factor 4. | |
Domain 2 of uPAR regulates single-chain urokinase-mediated angiogenesis through β1-integrin and VEGFR2 | |
Dynamic antibody-binding properties in the pathogenesis of HIT. | |
Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice | |
Erythrocytes as Carriers for Drug Delivery in Blood Transfusion and Beyond | |
Evidence-based mini-review: Is indium-labeled autologous platelet scanning predictive of response to splenectomy in patients with chronic immune thrombocytopenia? | |
Final results of the ReoPro readministration registry | |
Flow-dependent channel formation in clots by an erythrocyte-bound fibrinolytic agent | |
Heparin enhances uptake of platelet factor 4/heparin complexes by monocytes and macrophages | |
Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly | |
Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis | |
Human neutrophil peptides inhibit cleavage of von Willebrand factor by ADAMTS13: a potential link of inflammation to TTP. | |
ICAM-1-targeted thrombomodulin mitigates tissue factor-driven inflammatory thrombosis in a human endothelialized microfluidic model | |
The immune thrombocytopenia syndrome: a disorder of diverse pathogenesis and clinical presentation | |
International consensus report on the investigation and management of primary immune thrombocytopenia | |
Kinetics and mechanics of clot contraction are governed by the molecular and cellular composition of the blood | |
Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials | |
Management of antithrombotic therapy in adults with immune thrombocytopenia (ITP): a survey of ITP specialists and general hematologist-oncologists | |
Mechanisms of action of therapeutics in idiopathic thrombocytopenic purpura | |
Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer. | |
PAI-1-derived peptide EEIIMD prevents hypoxia/ischemia-induced aggravation of endothelin- and thromboxane-induced cerebrovasoconstriction | |
PF4/heparin complexes are T cell-dependent antigens | |
Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models. | |
Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells | |
Platelet Factor 4 Inhibits and Enhances HIV-1 Infection in a Concentration-Dependent Manner by Modulating Viral Attachment | |
Platelet glycoprotein IIb/IIIa inhibitors and thrombocytopenia: possible link between platelet activation, autoimmunity and thrombosis | |
Platelet-Specific Chemokines Contribute to the Pathogenesis of Acute Lung Injury. | |
Rapid Evaluation of Platelet Function With T2 Magnetic Resonance | |
Rational design and characterization of platelet factor 4 antagonists for the study of heparin-induced thrombocytopenia. | |
Safety of the thrombopoiesis-stimulating agents for the treatment of immune thrombocytopenia | |
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group | |
Structure of human urokinase plasminogen activator in complex with its receptor | |
T2 magnetic resonance: a diagnostic platform for studying integrated hemostasis in whole blood--proof of concept. | |
Targeting plasminogen activator inhibitor-1 in tetracycline-induced pleural injury in rabbits. | |
Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-reperfusion injury. | |
Thrombocytopenia in pregnancy | |
Tissue-Type Plasminogen Activator-A296-299 Prevents Impairment of Cerebral Autoregulation After Stroke Through Lipoprotein-Related Receptor-Dependent Increase in cAMP and p38. | |
TMA: beware of complements | |
tPA-S | |
tPA-S(481)A prevents impairment of cerebrovascular autoregulation by endogenous tPA after traumatic brain injury by upregulating p38 MAPK and inhibiting ET-1. | |
Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia | |
Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors. | |
Urokinase-type Plasminogen Activator (uPA) Promotes Angiogenesis by Attenuating Proline-rich Homeodomain Protein (PRH) Transcription Factor Activity and De-repressing Vascular Endothelial Growth Factor (VEGF) Receptor Expression | |
α-Defensins Induce a Post-translational Modification of Low Density Lipoprotein (LDL) That Promotes Atherosclerosis at Normal Levels of Plasma Cholesterol |